Alcon’s TobraDex ST treats inflammatory eye conditions
HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.
Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.
“This product was specifically designed to increase retention time on the eye, allowing the drug to calm inflammation and fight bacteria effectively,” said Stuart Raetzman, Alcon VP global marketing and area president for the United States. “Clinical studies indicated that 10 minutes after dosing, concentrations of TobraDex ST remained on the ocular surface at levels high enough to kill 99.9% of ocular bacteria.”
Good Neighbor Pharmacy gets top marks in customer satisfaction
VALLEY FORGE, Pa. A network of independent pharmacies across the United States got the highest customer service rating among chain drug stores in a study by J.D. Power and Associates.
Good Neighbor Pharmacy, which includes 3,700 independents, announced results of the 2010 national pharmacy study. The study, now in its fourth year and based on responses from 12,300 customers submitted in May and June, measured customer satisfaction based on experiences and perceptions of pharmacy patients and such key factors as the prescription ordering and pick-up process, the store, cost competitiveness and interactions with pharmacists and other staff.
“It is an honor for Good Neighbor Pharmacy owners and operators to be recognized by the patients they serve in this J.D. Power and Associates study,” Good Neighbor president Mike Cantrell said. “We recognize the importance of the community pharmacy where the pharmacist has the opportunity to help personally manage their patients’ health, and we are pleased to see the patients’ recognition of Good Neighbor Pharmacy as well.”
Teva sues Mylan for patent infringement over Copaxone
JERUSALEM Teva filed a complaint against a generic drug maker this week, asserting four patents for its multiple sclerosis drug are being infringed.
Teva filed a suit in the U.S. District Court for the Southern District of New York, asserting that Mylan is infringing on four patents related to Copaxone (glatiramer acetate injection). Teva also previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven "Orange Book" patents, covering the chemical composition of Copaxone, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.
Earlier this month, Teva also was involved in a patent dispute over the drug with Sandoz and Momenta Pharmaceuticals, in which a district court blocked the generic versions.